News

A new assay can help detect maternal-fetal incompatibilities in blood group and platelet antigens, which can lead to conditions such as FNAIT.

A Phase 2 clinical trial is underway to evaluate the safety and pharmacokinetics of RLYB212, a monoclonal antibody treatment for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT) in pregnant women at higher risk for alloimmunization, according to study information posted recently on ClinicalTrials.gov.  RLYB212 has the potential to significantly reduce risks to both mothers and […]

Non-invasive prenatal testing has enhanced safety and accuracy for alloimmunized pregnancies, including in those with FNAIT and HDFN.

A recent study found that the presence of certain antibodies may put patients at a higher risk of recurrent miscarriages.

In a recent study, functional assays more accurately assessed hemolysis risks in IVIG products, which are a frontline treatment in FNAIT.

Preclinical data from Rallybio suggested that RLYB212 may prevent fetal and neonatal allo-immune thrombocytopenia in high-risk pregnancies.

A recent study showed that those treated with IVIG may be at a greater risk of complications if they have certain medical conditions.

In a recent study, a 10 mL/kg standardized dose for platelet transfusions reduced neonatal platelet exposure without increasing risks.

The use of antenatal anti–human platelet antigen-1a (HPA-1a) screening for FNAIT has shown to be cost effective in Europe.

Comprehensive care strategies could improve outcomes for patients experiencing platelet transfusion refractoriness.